JOURNAL ARTICLE

23andMe Sells Gene-Testing Business to DNA Drug Maker Regeneron.

  • Published In: Bloomberg.com, 2025. P. N.PAG 1 of 3

  • Database: Business Source Ultimate 2 of 3

  • Authored By: Church, Steven; Smith, Gerry 3 of 3

Abstract

The genetic-testing company 23andMe has agreed to sell its data bank, containing DNA samples from approximately 15 million individuals, to Regeneron Pharmaceuticals for $256 million. Regeneron has pledged to uphold 23andMe's privacy policy, allowing customers to request the deletion of their personal information. 23andMe filed for bankruptcy due to financial struggles, with Regeneron set to continue running its personal genomic services pending approval of the sale by a judge. [Extracted from the article]

Additional Information

  • Source:Bloomberg.com. 2025/05, pN.PAG
  • Document Type:Article
  • Subject Area:Religion and Philosophy
  • Publication Date:2025
  • Accession Number:185262077
  • Copyright Statement:Copyright of Bloomberg.com is the property of Bloomberg, L.P. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.